Login / Signup

Design of Conformationally Constrained Acyl Sulfonamide Isosteres: Identification of N-([1,2,4]Triazolo[4,3- a]pyridin-3-yl)methane-sulfonamides as Potent and Selective hNaV1.7 Inhibitors for the Treatment of Pain.

Thilo FockenSultan ChowdhuryAlla ZenovaMichael E GrimwoodChristine ChabotTao ShengIvan HemeonShannon M DeckerMichael WilsonPaul BichlerQi JiaShaoyi SunClint YoungSophia LinSamuel J GoodchildNoah G ShuartElaine ChangZhiwei XieBowen LiKuldip KhakhGirish BankarMatthew WaldbrookRainbow KwanKaren NelkenbrecherParisa Karimi TariNavjot ChahalLuis SojoC Lee RobinetteAndrew D WhiteChien-An ChenYi ZhangJodie PangJae H ChangDavid H HackosJ P JohnsonCharles J CohenDaniel F OrtwineDaniel P SutherlinChristoph M DehnhardtBrian S Safina
Published in: Journal of medicinal chemistry (2018)
The sodium channel NaV1.7 has emerged as a promising target for the treatment of pain based on strong genetic validation of its role in nociception. In recent years, a number of aryl and acyl sulfonamides have been reported as potent inhibitors of NaV1.7, with high selectivity over the cardiac isoform NaV1.5. Herein, we report on the discovery of a novel series of N-([1,2,4]triazolo[4,3- a]pyridin-3-yl)methanesulfonamides as selective NaV1.7 inhibitors. Starting with the crystal structure of an acyl sulfonamide, we rationalized that cyclization to form a fused heterocycle would improve physicochemical properties, in particular lipophilicity. Our design strategy focused on optimization of potency for block of NaV1.7 and human metabolic stability. Lead compounds 10, 13 (GNE-131), and 25 showed excellent potency, good in vitro metabolic stability, and low in vivo clearance in mouse, rat, and dog. Compound 13 also displayed excellent efficacy in a transgenic mouse model of induced pain.
Keyphrases